| dc.contributor.author | Yazici, Y. | |
| dc.contributor.author | Yazici, H. | |
| dc.contributor.author | Adler, N. M. | |
| dc.date.accessioned | 2021-03-04T07:48:14Z | |
| dc.date.available | 2021-03-04T07:48:14Z | |
| dc.date.issued | 2008 | |
| dc.identifier.citation | Yazici Y., Adler N. M. , Yazici H., "Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called efficacy and safety trials: a survey of power considerations", RHEUMATOLOGY, cilt.47, sa.7, ss.1054-1057, 2008 | |
| dc.identifier.issn | 1462-0324 | |
| dc.identifier.other | av_5ff0d27c-9f77-4a59-9182-1865c5dec5df | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/66992 | |
| dc.identifier.uri | https://doi.org/10.1093/rheumatology/ken190 | |
| dc.description.abstract | Objectives: Many randomized clinical trials (RCTs) are labelled efficacy and safety while due consideration for power is provided only for efficacy outcomes. This in turn necessitates a discussion of the inadequacy of sample size (type II error) for identifying harm. This is particularly important in RCTs of TNF inhibitors as harm related to these agents is still a matter of debate. | |
| dc.language.iso | eng | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | İmmünoloji ve Romatoloji | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | ROMATOLOJİ | |
| dc.title | Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called efficacy and safety trials: a survey of power considerations | |
| dc.type | Makale | |
| dc.relation.journal | RHEUMATOLOGY | |
| dc.contributor.department | City University Of New York Brooklyn College , , | |
| dc.identifier.volume | 47 | |
| dc.identifier.issue | 7 | |
| dc.identifier.startpage | 1054 | |
| dc.identifier.endpage | 1057 | |
| dc.contributor.firstauthorID | 188777 | |
